Prescription Drug User Fee Act: Public Meeting
February 16, 2007 Agenda

8:00-8:45 am 

Registration

9:00 am 

Welcome  
Mark Barnett, M.P.H., FDA Moderator

9:05 am 

Opening Remarks
Andrew C. von Eschenbach, M.D.
U.S. Food and Drug Administration Commissioner

9:15-9:30 am  

Funding Human Drug Review: Resources for Drugs and Biologics
Janet Woodcock, M.D., Chief Medical Officer, FDA

9:30-9:45 am 

Background and History of PDUFA Program
Steven Galson, M.D., M.P.H., Director, FDA CDER

9:45-10:30 am

FDA Proposed Recommendations for PDUFA IV

Sound Financial Footing
Theresa Mullin, Ph.D., Assistant Commissioner for Planning
Pre-market Review
John K. Jenkins, M.D., Director, Office of New Drugs, FDA CDER
Information Management
Malcolm Bertoni, M.S., Director, Planning Staff, FDA Office of Planning

10:30-10:45 am

Break (15 minutes)    

10:45-11:30 am

Post-market Safety
Deborah Henderson, Director, Office of Executive Programs, FDA CDER
Advisory Review of Direct-to-Consumer Television Advertising
Jane Axelrad, J.D., Associate Director for Policy, FDA CDER

11:30-12:30 pm 

Lunch

12:30-4:00 pm 

Public Comment on FDA Proposed Recommendations for PDUFA IV

Patient Perspectives
Consumer Perspectives
Health Professional Perspectives
Industry Perspectives
Other Perspectives

4:00-4:15 pm

Break

4:15-5:00 pm

General Public Comments

5:00 pm  

Closing Comments
Theresa Mullin, Ph.D., Assistant Commissioner for Planning